Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jun;14(3):1183-1198.
doi: 10.1002/jcsm.13221. Epub 2023 Apr 1.

Sarcopenia and cardiovascular diseases: A systematic review and meta-analysis

Affiliations
Meta-Analysis

Sarcopenia and cardiovascular diseases: A systematic review and meta-analysis

Xinrong Zuo et al. J Cachexia Sarcopenia Muscle. 2023 Jun.

Abstract

Sarcopenia is an age-related disease and is often accompanied by other diseases. Now, many studies have shown that cardiovascular diseases (CVDs) may raise the incidence rate of sarcopenia. Therefore, the purpose of this study was to conduct a systematic review and meta-analysis to investigate the prevalence of sarcopenia in patients with CVDs compared with the general population, defined as relatively healthy non-hospitalized subjects. The databases of PubMed, Embase, Medline and Web of Science were searched for eligible studies published up to 12 November 2022. Two assessment tools were used to evaluate study quality and the risk of bias. Statistical analysis was conducted using STATA 14.0 and R Version 4.1.2. Thirty-eight out of the 89 629 articles retrieved were included in our review. The prevalence of sarcopenia ranged from 10.1% to 68.9% in patients with CVDs, and the pooled prevalence was 35% (95% confidence interval [95% CI]: 28-42%). The pooled prevalence of sarcopenia was 32% (95% CI: 23-41%) in patients with chronic heart failure (CHF), 61% (95% CI: 49-72%) in patients with acute decompensated heart failure (ADHF), 43% (95% CI: 2-85%) in patients with coronary artery disease, 30% (95% CI: 25-35%) in patients with cardiac arrhythmia (CA), 35% (95% CI: 10-59%) in patients with congenital heart disease and 12% (95% CI: 7-17%) in patients with unclassed CVDs. However, in the general population, the prevalence of sarcopenia varied from 2.9% to 28.6% and the pooled prevalence was 13% (95% CI: 9-17%), suggesting that the prevalence of sarcopenia in patients with CVDs was about twice compared with the general population. The prevalence of sarcopenia was significantly higher only in patients with ADHF, CHF and CA compared with the general population. There is a positive correlation between CVDs and sarcopenia. The prevalence of sarcopenia is higher in patients with CVDs than that in the general population. With global aging, sarcopenia has brought a heavy burden to individuals and society. Therefore, it is important to identify the populations with high-risk or probable sarcopenia in order to do an early intervention, such as exercise, to counteract or slow down the progress of sarcopenia.

Keywords: cardiac arrhythmia; cardiovascular diseases; coronary artery disease; heart failure; prevalence; sarcopenia.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

FIGURE 1
FIGURE 1
The flow chart of the literature selection in patients with cardiovascular diseases (CVDs) and the general population.
FIGURE 2
FIGURE 2
The pooled estimated prevalence rates of sarcopenia in patients with cardiovascular diseases (CVDs) and the general population. CI, confidence interval.
FIGURE 3
FIGURE 3
The pooled estimated prevalence rates of sarcopenia in patients with cardiovascular diseases (CVDs) and the general population by subgroups. ADHF, acute decompensated heart failure; CA, cardiac arrhythmia; CAD, coronary artery disease; CHD, congenital heart disease; CHF, chronic heart failure; CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.

Comment in

Similar articles

Cited by

References

    1. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr 1997;127:990S–991S. - PubMed
    1. Cruz‐Jentoft AJ, Sayer AA. Sarcopenia. The Lancet 2019;393:2636–2646. - PubMed
    1. Cao L, Morley JE. Sarcopenia is recognized as an independent condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD‐10‐CM) code. J Am Med Dir Assoc 2016;17:675–677. - PubMed
    1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021. - PMC - PubMed
    1. Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high‐income, middle‐income, and low‐income countries (PURE): a prospective cohort study. The Lancet 2020;395:795–808. - PMC - PubMed

Publication types